Literature DB >> 11821106

Should gamete donors be tested for spinal muscular atrophy?

Eduardo F Tizzano1, Ivón Cuscó, María Jesús Barceló, Juan Parra, Montserrat Baiget.   

Abstract

OBJECTIVE: To report two cases of spinal muscular atrophy (SMA) after artificial insemination and to discuss why genetic screening of the disease may be justified in gamete donors.
DESIGN: Case report.
SETTING: Academic departments of genetics and obstetrics. PATIENT(S): A 32-year-old woman with two successive assisted pregnancies. INTERVENTION(S): Molecular studies of the SMN1 (survival motor neuron), the determining gene of the disease. MAIN OUTCOME MEASURE(S); Prenatal testing to detect a homozygous deletion of the SMN1 gene; carrier diagnosis by quantitative analysis to detect a single or double dose of exon 7 in the SMN1 gene. RESULT(S): After a first assisted pregnancy, an SMA child with a homozygous deletion of the SMN1 gene was born. In the second assisted pregnancy, using sperm from a different donor, a fetus with a homozygous deletion of SMN1 was detected. Carrier status in the donor was confirmed by a single dose of SMN1 in the quantitative analysis. CONCLUSION(S): Genetic screening of SMA carrier status by quantitative analysis of the SMN1 gene should be performed in gamete donors when the recipient is a known carrier. Cost-benefit analysis should be made to consider the inclusion of the test in prospective gamete donor programs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11821106     DOI: 10.1016/s0015-0282(01)02994-6

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  2 in total

1.  Sperm donor suffers years later from inherited disease.

Authors:  D O E Gebhardt
Journal:  J Med Ethics       Date:  2002-08       Impact factor: 2.903

2.  Constitutive RB1 mutation in a child conceived by in vitro fertilization: implications for genetic counseling.

Authors:  Raquel H Barbosa; Fernando R Vargas; Evandro Lucena; Cibele R Bonvicino; Héctor N Seuánez
Journal:  BMC Med Genet       Date:  2009-07-29       Impact factor: 2.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.